Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharming Group has announced that it has been granted a SenterNovem subsidy of E905,000 for a period of three years. Pharming's wholly owned subsidiary, DNage will head a collaborative Research and Development effort to identify novel biomarkers and therapeutic targets, and to develop therapeutics for the treatment of premature ageing diseases.
Subscribe to our email newsletter
Under an International Innovation Subsidy granted by SenterNovem, an agency of the Dutch Ministry of Economic Affairs, DNage has initiated a project with the Eberhard Karls University in Tubingen, Germany, and Pyxis Discovery, to design new drug development tools aimed at discovery of new therapeutics to treat (premature) ageing diseases. In addition, DNage will collaborate with the Leiden University Medical Center to identify unique biomarkers of such diseases that will facilitate the clinical development of new therapies.
The company expects that this additional funding will accelerate its drug development program which involves the start of a clinical program later in 2008 to test a new product (Prodarsan) for the treatment of premature ageing diseases.